Celldex Therapeutics, Inc. CLDX today announced the pricing of an
underwritten public offering of 10,500,000 shares of its common stock, offered
at a price to the public of $3.85 per share for an aggregate offering of
$40,425,000 of common stock. The net proceeds to Celldex from this offering
are expected to be approximately $37,744,500, after deducting underwriting
discounts and commissions and other estimated offering expenses payable by
Celldex. Celldex has granted the underwriters a 30-day option to purchase up
to an aggregate of 1,575,000 additional shares of common stock to cover
overallotments, if any. All of the shares in the offering are to be sold by
Celldex. The offering is expected to close on or about February 29, 2012,
subject to customary closing conditions.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in